Environmental Tolerance for Sensitive Dry Skin and Post-Picosecond Laser Treatment
Conditions
Interventions
Control group A:Starting 1 month before the beginning of autumn (e.g. July 7/-7 days 2025), continue to use the first generation of Dry Sensitivity Cream for 2 months
Intervention Group B:Starting 1 month before the beginning of autumn (e.g. July 7/-7 days 2025), continue to use the second generation of Dry Sensitivity Cream for 2 months
Laser Intervention Group C:Picosecond laser treatment was applied immediately after applying the 2nd generation Dry Sensitivity Cream to the face, and the 2nd Generation Dry Sensitivity Cream was cont
Laser control group D:Picosecond laser treatment, with daily use of the first generation of dry sensitivity cream starting the day after surgery for 2 months
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Facial TEWL>=15 g/m^2/h; 2.10% lactate stinging test positive; 3. Age 18-60 years old, gender is not limited; 4. Have good compliance; 5. Sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Subjects who do not meet the eligibility criteria based on health examination; 2.Pregnant and breastfeeding women; 3.Those exposed to strong sunlight within 4 weeks; 4.Individuals who participated in any other drug clinical trial within three months prior to the start of this trial; 5.Frequent users of Chinese herbal medicine, sleeping pills, sedatives, tranquilizers, or other addictive drugs; 6.Alcoholics, individuals with mental illness; or those unable to follow medical advice and cooperate with treatment. 7.Individuals with cardiopulmonary insufficiency or severe underlying diseases. 8.Having other skin conditions that could interfere with the clinical assessment of sensitive skin and/or pose a risk to the subject, or having a history of other serious skin diseases. 9.Subjects who received systemic glucocorticoid therapy within 2 weeks prior to the baseline visit; 10.Subjects who received topical corticosteroid treatment within 2 weeks prior to the baseline visit; 11.Individuals with serious skin conditions such as melasma and skin tumors; 12.Individuals allergic to the following ingredients: Glycerin, Shea Butter (BUTYROSPERMUM PARKII Butter), Jojoba (SIMMONDSIA CHINENSIS) Seed Oil, Betaine, Safflower (CARTHAMUS TINCTORIUS) Seed Oil, Jojoba Esters, Saccharide Isomerate, Tetrahydro Methylpyrimidine Carboxylic Acid, 4-t-Butylcyclohexanol, Tocopherol (Vitamin E), Bisabolol, Triolein, Centella Asiatica Leaf Extract, Artemisia Annua Extract, Rice (ORYZA SATIVA) Lees Extract, Ginger (ZINGIBER OFFICINALE) Root Extract, Collagen Amino Acids, Butylene Glycol, Cetearyl Alcohol, Glycereth-26, Cetearyl Olivate, Sorbitan Olivate, Dimethicone, Pentaerythrityl Tetraethylhexanoate, Polyglyceryl-10 Myristate, Behenyl Alcohol, Hydroxyacetophenone, 1,2-Pentanediol, Ammonium Acryloyldimethyltaurate/VP Copolymer, Disodium EDTA, Hydrogenated Lecithin, Tromethamine, 1,2-Hexanediol, Citric Acid, Sodium Citrate, Dipotassium Glycyrrhizate, Hydroxyphenyl Propamidobenzoic Acid.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percutaneous water loss of the skin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity Scale Score;Adverse Event Record;Skin elasticity;Erythema a*;Clinical Symptom Assessment;Stratum corneum hydration;Sebum secretion amount;FACE-Q Skin Satisfaction Scale;VISIA Facial Image Analysis;GAIS Scoring; | — |
Countries
China
Contacts
Public ContactLi Xia
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed